{"type":"trials","record":{"id":41794,"source_id":"clinicaltrials-gov","external_id":"NCT02230228","title":"Phase 1 Safety Study of ALK-001 in Healthy Volunteers","brief_summary":"This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Alkeus Pharmaceuticals, Inc.","enrollment":40,"countries":[],"start_date":"2014-04-01","completion_date":"2015-02-01","last_update_date":"2025-04-27","source_url":"https://clinicaltrials.gov/study/NCT02230228","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"21 Years to 70 Years","comparator":null,"organization":"Alkeus Pharmaceuticals, Inc.","interventions":["ALK-001 (No generic name)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety of 4-week daily dosing of ALK-001 in healthy adults. — 4 weeks"],"design_description":"NA · SINGLE GROUP · BASIC SCIENCE · NONE","source_has_results":false},"controlled_terms":["Stargardt Disease","Age-related Macular Degeneration","Other Retinal Dystrophies","ALK-001 (No generic name)"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02230228","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-04-01 to 2015-02-01","comparator":null,"confidence":"structured-source","population":"ALL · 21 Years to 70 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.872Z","intervention":["ALK-001 (No generic name)"],"participants":40,"study_design":"NA · SINGLE GROUP · BASIC SCIENCE · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety of 4-week daily dosing of ALK-001 in healthy adults. — 4 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41794","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}